Kidneys function in glucose homeostasis regulation and its therapeutic implications

• Authors: Otto-Buczkowska Ewa , Tucholski Krzysztof
• Languages of publication: EN

Keywords

EN

gluconeogenesis; glycogenolysis; glucose reabsorption sodium-dependent glucose cotransporters (SGLT s); SGLT 2; cotransporter inhibitors.

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2013
• Issue: 1
• Pages: 34-37

Contributors

author

Otto-Buczkowska Ewa

author

Tucholski Krzysztof

References

• Ficek R, Chudek J, Więcek A. Blokowanie zwrotnego wchłaniania glukozy w cewkach nerkowych jako nowa potencjalna metoda leczenia cukrzycy. W: Otto Buczkowska E, red. Cukrzyca w populacji wieku rozwojowego – co nowego? Wrocław:Cornetis; 2009: 244–250.
• Otto Buczkowska E. The role of the human kidney for glucose homeostasis. Wiad Lek 2004; 57: 158–160.
• Otto Buczkowska E. Mechanizmy kontroli metabolicznej homeostazy organizmu. W: Otto Buczkowska E, red. Cukrzyca – patogeneza, diagnostyka, leczenie. Warszawa: Borgis; 2005: 9–82.
• Otto Buczkowska E. Homeostaza glukozy. W: Otto Buczkowska E, red. Pediatria – co nowego? Wrocław: Cornetis; 2011:332–345.
• Pérez López G, González Albarrán O, Cano Megías M. Sodium-glucose cotransporter type 2 inhibitors (SGLT 2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus. Nefrologia 2010; 30: 618–625.
• Mitrakou A. Kidney: its impact on glucose homeostasis and hormonal regulation. Diabet Res Clin Pract 2011; 93(Suppl. 1):S66–S72.
• Mather A, Pollock C. Glucose handling by the kidney. Kidney Int 2011; (Suppl. 120): S1–S6.
• Braga VA. Teaching the renal tubular reabsorption of glucose using two classic papers by Shannon et al. Adv Physiol Educ 2011; 35: 114–116.
• Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.Diab Med 2010; 27: 136–142.
• Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53: 875–883.
• Hummel CS , Lu C, Loo DD, et al. Glucose transport by human renal Na+/D-glucose cotransporters SGLT 1 and SGLT 2. Am J Physiol Cell Physiol 2011; 300: C14–C21.
• List JF, Whaley JM. T-glucose dynamics and mechanistic implications of SGLT 2 inhibitors in animals and humans. Kidney Int 2011; (Suppl. 120): S20–S27.
• Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733–794.
• Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.Kidney Int 2009; 75: 1272–1277.
• Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009;25: 671–681.
• DeFronzo RA , Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diab Obes Metab 2012; 14: 5–14.
• Hardman TC , Rutherford P, Dubrey SW , et al. Sodium-glucose co-transporter 2 inhibitors: from apple tree to ‘Sweet Pee’. Curr Pharm Des 2010; 16: 3830–3838
• Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabet Obes Metab 2009; 11: 79–88.
• Jabbour SA , Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279–1284.
• Nomura S. Renal sodium-dependent glucose cotransporter 2 (SGLT 2) inhibitors for new anti-diabetic agent. Curr Top Med Chem 2010; 10: 411–418.
• Calado J, Santer R, Rueff J. Effect of kidney disease on glucose handling (including genetic defects). Kidney Int 2011; (Suppl.120): S7–S13.
• Enigk U, Breitfeld J, Schleinitz D, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT 2) in glucose homeostasis. Pharmacogenomics 2011; 12: 1119–1126.
• Santer R, Calado J. Familial renal glucosuria and SGLT 2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133–141.
• Vallon V, Platt KA , Cunard R, et al. SGLT 2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011;22: 104–112.
• Aires I, Calado J. BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus.Curr Opin Investig Drugs 2010; 11: 1182–1190.
• Basile J. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.Postgrad Med 2011; 123: 38–45.
• Bołdys A, Okopień B. Inhibitors of type 2 sodium glucose co-transporters – a new strategy for diabetes treatment. Pharmacol Rep 2009; 61: 778–784.
• Calado J. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.Drugs 2009; 12: 785–798.
• Chao EC, Henry RR . SGLT 2 inhibition – a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010; 9: 551–559.
• Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT 2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268–276.
• Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT 2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513–519.
• Meng W, Ellsworth BA, Nirschl AA , et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT 2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145–1149.
• Pfister M, Whaley JM, Zhang L, et al. Inhibition of SGLT 2: a novel strategy for treatment of type 2 diabetes mellitus. Clin Pharmacol Ther 2011; 89: 621–625.
• Vaidya HB, Goyal RK . Exploring newer target sodium glucose transporter 2 for the treatment of diabetes mellitus. Mini Rev Med Chem 2010; 10: 905–913.
• Washburn WN. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem 2009; 52: 1785–1794.
• White JR Jr. Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT 2 inhibition. Clin Diab 2010; 28: 5–10.
• Chao EC. A paradigm shift in diabetes therapy – dapagliflozin and other SGLT 2 inhibitors. Discov Med 2011; 11: 255–263.
• DeFronzo RA , Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diab Obes Metab 2012; 14: 5–14.
• Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011; 32: 63–71.
• Hardman TC , Dubrey SW . Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diab Ther 2011; 2: 133–145.
• Isaji M. Sergliflozin etabonate, a selective SGLT 2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009; 609: 148–154.
• Ly JP, Onay T, Sison K, et al. The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol 2011; 22: 113–123.
• Ueta K, Ishihara T, Matsumoto Y, et al. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005; 76: 2655–2668